摘要
目的了解某院患者血小板生成素受体(TPO)激动剂阿伐曲泊帕片的使用情况,评价某三甲医院阿伐曲泊帕临床应用的合理性,为该药在临床的规范化应用提供参考。方法建立阿伐曲泊帕用药合理性的评价标准,包括适应症、用药时机、用法用量、疗程和相互作用等,回顾性分析2023年11月~2024年5月某三甲医院使用阿伐曲泊帕患者的临床资料,评价阿伐曲泊帕使用的合理性。结果共有30例患者使用了阿伐曲泊帕,其在治疗中涉及35例次择期行诊断性操作或者手术。其中符合申请用药的适应症的有27例次(90.0%),符合适应症且完成操作或手术的有10例次(33.3%),符合适应症但未完成操作或手术的有8例次(22.8%),不符合适应症的有8例次(22.8%)。35例次患者中合并其他升血小板方案有28例次,符合适应症且进行操作或手术的,用药在操作或手术前7例次,给药时长(6.2±1.6)天。结论该院阿伐曲泊帕不合理使用现象突出,需要采取措施规范用药合理性。建议今后应通过严格把关临时用药申请医保适应症和医嘱审核系统、药师定期医嘱点评等手段进一步规范该药的临床应用。
OBJECTIVE To understand the use of thrombopoietin receptor(TPO)agonist Avatrombopag tablets in a hospital,evaluate the rationality of the clinical application of Avatrombopag in a tertiary hospital,and provide recommendations for the standardized application of the drug in clinical practice.METHODS To establish the evaluation criteria for the rationality of avatrombopag medication,including indications,timing of medication,usage and dosage,course of treatment and interaction,etc.,and retrospectively analyzed the use of avatrombopag in a tertiary hospital from November 2023 to May 2024 Clinical data of patients to evaluate the rationale for the use of avatrombopag.RESULTS A total of 30 patients were treated with avatrombopag,which involved 35 elective diagnostic procedures or surgery.Among them,27 cases(90.0%)met the indications for drug application,10 cases(33.3%)Strait Pharmaceutical Journal Vol.37 No.112025 met the indications and completed the operation or surgery,and 8 cases met the indications but did not complete the operation or surgery(22.8%),8 cases(22.8%)did not meet the indications.Among the 35 cases,28 cases were combined with other platelet-raising regimens.For those who met the indications and underwent operation or surgery,the medication was administered in 7 cases before the operation or surgery,and the administration time was(6.2±1.6)days.CONCLUSION The phenomenon of irrational use of avatrombopag in our hospital is prominent,and measures should be taken to standardize the rationality of drug use.It is suggested that in the future,the clinical application of this drug should be further standardized by strictly controlling the medical insurance indications and doctor′s order review system for temporary drug application,and the pharmacist′s regular doctor′s order review.
作者
龚伟
蔡海峰
龚银华
周良
GONG Wei;CAI Hai-feng;GONG Yin-hua;ZHOU Liang(Department of Pharmacy,The first affiliated hospital of Soochow University,Shuzhou 215006,China;Department of Pharmacy,The Fifth People′s Hospital of Wuxi,Wuxi 214016,China)
出处
《海峡药学》
2025年第11期67-71,共5页
Strait Pharmaceutical Journal
